Trials / Completed
CompletedNCT00202579
Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
Evaluation of the Effects on Peripheral and Central Haemodynamics Parameters, Safety, and Tolerance of Three-hour Intravenous Perfusion (0.1 mg/kg) of Ivabradine Given to Severe Congestive Heart Failure Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Institut de Recherches Internationales Servier · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivabradine |
Timeline
- Start date
- 2004-09-01
- Completion
- 2006-02-01
- First posted
- 2005-09-20
- Last updated
- 2024-07-25
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00202579. Inclusion in this directory is not an endorsement.